Atypical hemolytic uremic syndrome (aHUS) is an extremely rare, complement-mediated disease characterized by acute kidney injury, thrombocytopenia, and microangiopathic hemolytic anemia that occurs with a reported annual incidence for all ages ranging from 0.23 to 1.9 million.

Hyperkalaemia (HK) is a potentially life-threatening condition with serious clinical and economic consequences. There is a U-shape relationship between serum potassium (K⁺) levels, mortality and major adverse cardiovascular events in patients with chronic kidney disease (CKD).

Chronic kidney disease (CKD) is highly prevalent worldwide, with up to 14% of people affected in some regions, and the number of potential or productive life years lost due to premature death or disability is rising, regardless of the underlying cause of renal damage (1, 2). It is estimated that 5 million individuals will require renal replacement therapy by 2030, presenting a substantial burden on health services worldwide.